Recent blog posts
Familial Mediterranean fever Indication Strategy Report 2026: MEFV, Trials and Deals
Latest Hotspot
8 min read
Familial Mediterranean fever Indication Strategy Report 2026: MEFV, Trials and Deals
21 July 2026
Familial Mediterranean fever indication strategy report covering epidemiology, MEFV biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Adult-onset Still disease Indication Strategy Report 2026: IL-1β, Trials and Deals
Latest Hotspot
8 min read
Adult-onset Still disease Indication Strategy Report 2026: IL-1β, Trials and Deals
21 July 2026
Adult-onset Still disease indication strategy report covering epidemiology, IL-1β biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Juvenile idiopathic arthritis Indication Strategy Report 2026: IL-6R, Trials and Deals
Latest Hotspot
8 min read
Juvenile idiopathic arthritis Indication Strategy Report 2026: IL-6R, Trials and Deals
21 July 2026
Juvenile idiopathic arthritis indication strategy report covering epidemiology, IL-6R biology, active trials, competition and deal signals using PatSnap MCP...
Read →
Peripheral T-cell lymphoma Indication Strategy Report 2026: CD30, Trials and Deals
Latest Hotspot
8 min read
Peripheral T-cell lymphoma Indication Strategy Report 2026: CD30, Trials and Deals
21 July 2026
Peripheral T-cell lymphoma indication strategy report covering epidemiology, CD30 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Burkitt lymphoma Indication Strategy Report 2026: MYCNUT, Trials and Deals
Latest Hotspot
8 min read
Burkitt lymphoma Indication Strategy Report 2026: MYCNUT, Trials and Deals
21 July 2026
Burkitt lymphoma indication strategy report covering epidemiology, MYCNUT biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Wilms tumor Indication Strategy Report 2026: IGF-2, Trials and Deals
Latest Hotspot
8 min read
Wilms tumor Indication Strategy Report 2026: IGF-2, Trials and Deals
21 July 2026
Wilms tumor indication strategy report covering epidemiology, IGF-2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Hepatoblastoma Indication Strategy Report 2026: CTNNB1, Trials and Deals
Latest Hotspot
8 min read
Hepatoblastoma Indication Strategy Report 2026: CTNNB1, Trials and Deals
21 July 2026
Hepatoblastoma indication strategy report covering epidemiology, CTNNB1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Gallbladder cancer Indication Strategy Report 2026: HER2, Trials and Deals
Latest Hotspot
8 min read
Gallbladder cancer Indication Strategy Report 2026: HER2, Trials and Deals
21 July 2026
Gallbladder cancer indication strategy report covering epidemiology, HER2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Appendiceal cancer Indication Strategy Report 2026: KRAS, Trials and Deals
Latest Hotspot
8 min read
Appendiceal cancer Indication Strategy Report 2026: KRAS, Trials and Deals
21 July 2026
Appendiceal cancer indication strategy report covering epidemiology, KRAS biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Small bowel adenocarcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
Latest Hotspot
8 min read
Small bowel adenocarcinoma Indication Strategy Report 2026: EGFR, Trials and Deals
21 July 2026
Small bowel adenocarcinoma indication strategy report covering epidemiology, EGFR biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Gastrointestinal neuroendocrine tumor Indication Strategy Report 2026: SSTR2, Trials and Deals
Latest Hotspot
8 min read
Gastrointestinal neuroendocrine tumor Indication Strategy Report 2026: SSTR2, Trials and Deals
21 July 2026
Gastrointestinal neuroendocrine tumor indication strategy report covering epidemiology, SSTR2 biology, active trials, competition and deal signals using PatSnap...
Read →
Pancreatic neuroendocrine tumor Indication Strategy Report 2026: SSTR2, Trials and Deals
Latest Hotspot
8 min read
Pancreatic neuroendocrine tumor Indication Strategy Report 2026: SSTR2, Trials and Deals
21 July 2026
Pancreatic neuroendocrine tumor indication strategy report covering epidemiology, SSTR2 biology, active trials, competition and deal signals using PatSnap MCP...
Read →